Uncategorized

VIDEO: Kala readies to launch Inveltys for cataract surgery

by Healio ophthalmology • 2018/11/08 • 0 Comments

CHICAGO — At the Ophthalmology Innovation Summit at AAO, Mark Iwicki, chairman and CEO of Kala Pharmaceuticals, discusses the company’s plans to launch Inveltys (loteprednol etabonate ophthalmic suspension 1%), a twice-daily topical steroid, for the treatment of inflammation and pain following cataract surgery.

Full Story →

← The Global Ophthalmic Drugs Market is Expected to Witness a CAGR of 6.3% During 2018-2024 – The Loss of Patent is the Most Important Aspect Imposing Major Threats to Market Leaders – ResearchAndMarkets.com

Mutual of Omaha Launches New Vision Insurance and Enhanced Dental Product →

Post navigation